Published in Eur Respir J on June 11, 2008
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med (2012) 1.19
Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. Pulm Circ (2013) 1.05
Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids. Annu Rev Physiol (2013) 1.05
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One (2012) 1.00
Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2011) 0.95
Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.95
Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment. Curr Opin Pharmacol (2010) 0.91
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol (2010) 0.91
Regulation of soluble guanylyl cyclase-alpha1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR. Am J Physiol Lung Cell Mol Physiol (2009) 0.90
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax (2015) 0.90
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade. PLoS One (2012) 0.88
New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol (2011) 0.87
RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase. Nitric Oxide (2011) 0.86
Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther (2014) 0.83
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. Br J Pharmacol (2015) 0.83
Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension. Am J Respir Cell Mol Biol (2016) 0.81
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS One (2015) 0.80
Oxidant-redox regulation of pulmonary vascular responses to hypoxia and nitric oxide-cGMP signaling. Cardiol Rev (2010) 0.80
Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension. PLoS One (2013) 0.80
Differential sensitivities of pulmonary and coronary arteries to hemoglobin-based oxygen carriers and nitrovasodilators: study in a bovine ex vivo model of vascular strips. Vascul Pharmacol (2009) 0.79
Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Rev Respir Med (2011) 0.77
Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease. Circ Res (2017) 0.76
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.76
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.76
Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern. Eur Respir J (2009) 0.75
Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat. Ther Clin Risk Manag (2016) 0.75
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ (2015) 0.75
Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Ther Adv Chronic Dis (2017) 0.75
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther (2017) 0.75
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.75
Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment. Pulm Circ (2016) 0.75
Update on novel targets and potential treatment avenues in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2016) 0.75
Riociguat: PATENT-1 Study. Glob Cardiol Sci Pract (2014) 0.75
Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center. Cardiol Ther (2015) 0.75
Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension. Antioxidants (Basel) (2017) 0.75
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences. Respir Med Case Rep (2017) 0.75
Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart (2016) 0.75
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Fibreoptic vs videolaryngoscopic (C-MAC(®) D-BLADE) nasal awake intubation under local anaesthesia. Anaesthesia (2015) 5.75
A prokaryotic potassium ion channel with two predicted transmembrane segments from Streptomyces lividans. EMBO J (1995) 2.86
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood (1990) 2.54
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Hemolysis determinant common to Escherichia coli hemolytic plasmids of different incompatibility groups. J Bacteriol (1980) 2.51
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.49
Induction of c-fos during myelomonocytic differentiation and macrophage proliferation. Nature (1985) 2.34
Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14
Neoalveolarisation contributes to compensatory lung growth following pneumonectomy in mice. Eur Respir J (2007) 2.11
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
Limitations of sniff nasal pressure as an outcome measurement in amyotrophic lateral sclerosis patients in a clinical trial. Respiration (2012) 2.02
Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J (2008) 1.97
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Multiple copies of hemolysin genes and associated sequences in the chromosomes of uropathogenic Escherichia coli strains. J Bacteriol (1984) 1.87
Relationship between plasmid and chromosomal hemolysin determinants of Escherichia coli. J Bacteriol (1983) 1.87
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Uremia-related vascular calcification: more than apatite deposition. Kidney Int (2006) 1.84
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol (2000) 1.73
Conserved outer membrane protein of Neisseria meningitidis involved in capsule expression. Infect Immun (1992) 1.67
The dorsolateral, suboccipital, transcondylar approach to the lower clivus and anterior portion of the craniocervical junction. Neurosurgery (1991) 1.67
Differential expression of c-fos in hematopoietic cells: correlation with differentiation of monomyelocytic cells in vitro. EMBO J (1984) 1.63
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J (2008) 1.62
Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol (1988) 1.61
Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion. EMBO J (1985) 1.60
Role of small calibre chest tube drainage for iatrogenic pneumothorax. Thorax (1990) 1.57
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Cyclic nucleotide-gated channels on the flagellum control Ca2+ entry into sperm. J Cell Biol (1998) 1.55
Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet (1972) 1.55
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
Rupture and dissection in pulmonary artery aneurysms: incidence, cause, and treatment--review and case report. J Thorac Cardiovasc Surg (2001) 1.49
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J (2009) 1.44
Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) (1985) 1.44
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Wounding a fibroblast monolayer results in the rapid induction of the c-fos proto-oncogene. EMBO J (1986) 1.42
Subacute sclerosing panencephalitis: a review. Curr Top Microbiol Immunol (1972) 1.41
Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg (1989) 1.40
Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome. Hum Mol Genet (1999) 1.40
Neural drive to the diaphragm after lung volume reduction surgery. Chest (1999) 1.39
Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J (2004) 1.39
Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. Am J Transplant (2014) 1.39
Function and expression of the epithelial Ca(2+) channel family: comparison of mammalian ECaC1 and 2. J Physiol (2001) 1.39
Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release (2005) 1.38
Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest (2005) 1.38
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
Co-transfection of normal NIH/3T3 DNA and retroval LTR sequences: a novel strategy for the detection of potential c-onc genes. EMBO J (1984) 1.35
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
[Toxicology of ethyleneglycol-monoethyl ether]. Arzneimittelforschung (1971) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Isolation of infectious measles virus in measles encephalitis. Lancet (1972) 1.35
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
Morphogenesis and structure of a virus in cells cultured from brain tissue from two cases of multiple sclerosis. Lab Invest (1973) 1.31
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27